A phase II study of capecitabine and lapatinib in advanced refractory colorectal adenocarcinoma: A Wisconsin Oncology Network study

BACKGROUND: Prognosis remains poor after progression on first-line chemotherapy for colorectal adenocarcinoma, and inactivation of the EGFR pathway with monoclonal antibodies is an effective treatment strategy in selected patients with metastatic disease. Lapatinib is an oral EGFR and HER-2 dual tyr...

詳細記述

保存先:
書誌詳細
主要な著者: Frank, Daniel, Jumonville, Alcee, LoConte, Noelle K, Schelman, William R, Mulkerin, Daniel, Lubner, Sam, Richter, Katie, Winterle, Natalie, Wims, Mary Beth, Dietrich, Leah, Winkler, J. Mitchell, Volk, Michael, Kim, KyungMann, Holen, Kyle D.
フォーマット: Artigo
言語:Inglês
出版事項: Pioneer Bioscience Publishing Company 2012
主題:
Original Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC3397648/
https://ncbi.nlm.nih.gov/pubmed/22811876
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.2078-6891.2011.049
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料